Bharat Biotech’s Covaxin cleared for 6-12 age group

News Headline ::

DU Pro-VC, 3 others go to Finland to purchase lifts Hamas negotiators arrive in Egypt for Gaza truce talks Three arrested and charged over Sikh activist’s killing in Canada Mithila wins best actress award in Delhi Former aide tells Donald Trump trial of 2016 campaign ‘crisis’ India removes prohibition for onion export Nat’l guideline on heat-related health risks to be launched tomorrow Severe heatwave prevails in 4 dists, Dhaka may witness rain: BMD Border killings by BSF rise despite repeated pledges Derailed train in Gazipur not salvaged in 24 hours after collision

Home

Exclusive, Lead News, World news

Bharat Biotech’s Covaxin cleared for 6-12 age group

Shawdesh Desk:

The Drugs Controller General of India (DCGI) today gave restricted use authorisation to Bharat Biotech’s Covaxin for children between the age group of 6-12 amid an uptick in the Covid cases in schools.

The DCGI has directed the vaccine maker to submit the safety data, including the data on the adverse events, with due analysis every 15 days for the first two months.

After two months, Bharat Biotech has been asked to submit the data monthly for up to 5 months.

Covaxin was granted Emergency Use Listing by the DCGI for the age group of 12 to 18 years on December 24, 2021.

Further, the DCGI also granted emergency use authorisation to Corbevax for children between the age of 5-12 years. The Corbevax is currently being administered to children in the age group of 12-14.

Covid-19 vaccinations for adolescents in the age group of 15-18 years commenced on January 3 this year. The drive was later expanded to include children aged above 12 years last month.